National and Kapodistrian University of Athens
Η σημασία των μεταλλάξεων του γονιδίου της φωσφολαμβάνης στην εκδήλωση διατατικής μυοκαρδιοπάθειας
Abstract
dc:descriptionAim: Dilated cardiomyopathy is considered as a genetic disease and a number of mutations have been found to be involved in the disease pathogenesis. Phospholamban is a myocardial protein that regulates myocardial calcium handling and cardiac contractility. The aim of the study was to investigate the association of Phospholamban gene mutations with dilated cardiomyopathy. Methods and Results: Sequencing mutation screening of phospholamban gene was performed in 112 (83 males, average age: 49±13, LVEF: 29±8%) independent dilated cardiomyopathy patients. Two phospolamban gene’s mutations were indentified the L39 stop and R14del. The L39 stop mutation resulted in the loss of phospholamban function while the R14del was identified in 2 patients (1 heterozygous and 1 homozygous) and the R14del mutation resulted in increased protein function. The L39 stop mutation was identified in 1 other patient (heterozygous). The Pedigree's members of these 3 patients were evaluated including clinical examination, echo study, 24 h-Holter ECG recording and phospholamban mutation screening. Two of the 19 evaluated members of the L39 stop heterozygous patient's pedigree presented the disease. Both diseased members were also found heterozygous for the L39 stop mutation. One of the 30 evaluated members of the L39 stop homozygous patient's pedigree presented the disease. The patient member was also found homozygous for the L39 stop mutation. Pedigree analysis of the R14del heterozygous patient revealed that 5 of the 27 evaluated members presented the disease. All diseased members were also found heterozygous for the R14del mutation. Two R14del heterozygous patients had fitted an AICD, after sustained ventricular tachycardia episodes and one other R14del heterozygous patient presented non sustain ventricular tachycardia episodes during 24-h Holter ECG recording. Interestingly R14del heterozygous patients presented mild left ventricular dilatation (LVEDD: 55±2 mm) and mild left ventricular systolic dysfunction (LVEF: 42±10%). On the contrary, L39 stop mutation patients presented severe left ventricular dilatation (LVEDD: 65±2 mm p:0,01) as also as severe left ventricular systolic dysfunction (LVEF: 28±5% p:0,05), while none of them presented ventricular tachycardia episodes during 24-h Holter ECG recording. Conclusions: The phospholamban gene mutations L39 stop and R14del are associated with dilated cardiomyopathy. Phospolamban L39 stop dilated cardiomyopathy is characterized by severe left ventricular dilatation and systolic dysfunction without ventricular tachycardia episodes, while R14del dilated cardiomyopathy is characterized mainly by ventricular tachycardia episodes.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kolokathis, Fotios
- Κολοκάθης, Φώτιος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/24347